Blood Transfusion Management in Polycythemia Vera

Introduction to Polycythemia Vera

• Polycythemia vera (PV) is characterized by excessive red blood cell production leading to increased blood viscosity, which is the limiting factor in oxygen delivery to tissues 2

Treatment Goals and Considerations

• The primary treatment goal in PV is to reduce hematocrit below 45% through phlebotomy and cytoreductive therapy to prevent thrombotic complications 1, 3

Transfusion Considerations

• Blood transfusions are generally contraindicated in polycythemia vera patients as they would further increase red cell mass and exacerbate hyperviscosity, potentially increasing thrombotic risk 1
• Transfusions should only be considered in exceptional circumstances, such as perioperative blood loss requiring immediate replacement, development of secondary bone marrow failure, or transformation to myelofibrosis with cytopenias 1

Special Transfusion Precautions

• When transfusion is absolutely necessary, use leukoreduced blood products to minimize inflammatory reactions 1
• Administer small-volume transfusions with careful monitoring of hematocrit levels 1
• Perform therapeutic phlebotomy before transfusion if the clinical situation allows, to maintain hematocrit below 45% 1

Managing Thrombotic Risk

• Low-dose aspirin therapy should be continued during the perioperative period to reduce thrombotic risk 1, 3
• Closely monitor hematocrit levels before, during, and after transfusion 1

Platelet Transfusions

• Platelet transfusions should be avoided in PV patients with thrombocytosis 1
• PV patients may have qualitative platelet defects that can contribute to bleeding risk despite normal or elevated platelet counts 1
• Decreased platelet number and function have been described in conditions with polycythemia 2

Alternative Management Approaches

• Phlebotomy to maintain hematocrit <45% (or approximately 42% for women and certain populations) 4
• Low-dose aspirin (81-100 mg/day) for all patients without contraindications 3, 4
• Cytoreductive therapy (hydroxyurea or interferons) for high-risk patients (age >60 years and/or history of thrombosis) 3
• Ruxolitinib for patients who are resistant to or intolerant of hydroxyurea 5